ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 240 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $26,426 | -34.7% | 659 | -24.5% | 0.00% | -33.3% |
| Q4 2022 | $40,446 | +12.4% | 873 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $36,000 | -30.8% | 873 | 0.0% | 0.01% | -25.0% |
| Q2 2022 | $52,000 | -5.5% | 873 | +15.6% | 0.01% | +14.3% |
| Q1 2022 | $55,000 | -12.7% | 755 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $63,000 | -7.4% | 755 | 0.0% | 0.01% | -11.1% |
| Q3 2021 | $68,000 | -5.6% | 755 | 0.0% | 0.01% | -10.0% |
| Q2 2021 | $72,000 | -24.2% | 755 | -9.0% | 0.01% | -28.6% |
| Q1 2021 | $95,000 | -24.0% | 830 | -8.1% | 0.01% | -30.0% |
| Q4 2020 | $125,000 | +101.6% | 903 | +20.4% | 0.02% | +66.7% |
| Q3 2020 | $62,000 | +77.1% | 750 | +69.7% | 0.01% | +71.4% |
| Q2 2020 | $35,000 | +75.0% | 442 | 0.0% | 0.01% | +40.0% |
| Q1 2020 | $20,000 | – | 442 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |